NDAORALTABLET
Approved
Dec 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAFYRAL is an oral contraceptive tablet combining drospirenone and ethinyl estradiol with added levomefolate calcium to reduce neural tube defect risk in users. It is indicated for pregnancy prevention in women of reproductive age. The formulation leverages hormonal contraception with periconceptional folate supplementation to address a key safety concern.
$0.008BPart D
Peak4.2 years to LOEProduct is at peak lifecycle stage with modest Part D engagement, indicating stable but limited commercial opportunity with small promotional team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on SAFYRAL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.